澳大利亚脑膜炎球菌监测：报告期为 2024 年 1 月 1 日至 3 月 31 日。

Q3 Medicine

Communicable diseases intelligence (2018) Pub Date : 2024-11-21 DOI:10.33321/cdi.2024.48.53

Monica M Lahra, Sonya Natasha Hutabarat, Tiffany R Hogan

{"title":"澳大利亚脑膜炎球菌监测：报告期为 2024 年 1 月 1 日至 3 月 31 日。","authors":"Monica M Lahra, Sonya Natasha Hutabarat, Tiffany R Hogan","doi":"10.33321/cdi.2024.48.53","DOIUrl":null,"url":null,"abstract":"Abstract: The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year is contained in the AMSP annual reports.","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2024.\",\"authors\":\"Monica M Lahra, Sonya Natasha Hutabarat, Tiffany R Hogan\",\"doi\":\"10.33321/cdi.2024.48.53\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year is contained in the AMSP annual reports.\",\"PeriodicalId\":36867,\"journal\":{\"name\":\"Communicable diseases intelligence (2018)\",\"volume\":\"48 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Communicable diseases intelligence (2018)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33321/cdi.2024.48.53\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communicable diseases intelligence (2018)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33321/cdi.2024.48.53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

摘要：澳大利亚脑膜炎球菌监测计划（AMSP）的参考实验室利用培养和分子技术报告经实验室检测确诊的侵袭性脑膜炎球菌病（IMD）病例数数据。季度报告中的数据仅限于按辖区和血清群（如果已知）描述侵袭性脑膜炎球菌病病例数，并在 2024 年扩展到包括头孢曲松、青霉素、环丙沙星和利福平的抗菌药耐药性数据。AMSP 年度报告中载有对每个日历年 IMD 实验室确诊情况的全面分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2024.

Abstract: The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year is contained in the AMSP annual reports.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Communicable diseases intelligence (2018) Medicine-Medicine (all)

CiteScore

1.90

自引率

0.00%

发文量